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REVIEW
Background: The multiple effects (ie, pleiotropic effects of statins) have received increasing
recognition and may have clinical applicability across a broad range of cardiovascular and
noncardiovascular conditions.
Objective: To determine the relevance and significance of ongoing clinical trials of the
pleiotropic effects of statins, focusing on nonlipid effects.
Method: Ongoing trials were identified through personal communication, reports presented
at scientific meetings (2000–2004), and queries made to AstraZeneca, Bristol-Myers Squibb
Co, Merck & Co, Novartis, and Pfizer, manufacturers of the currently marketed statins.
Published trials and other source material were identified through electronic searches on
MEDLINE (1990–2003), abstract books, and references identified from bibliographies of
pertinent articles. Eligible studies were the clinical trials of statins currently under way in
which primary or secondary outcomes included the statins’ nonlipid (ie, pleiotropic) effect(s).
Data were extracted and trial quality was assessed by the authors.
Results: Of the 22 ongoing trials of the nonlipid effects of statins identified,
10 assessed inflammatory markers and plaque stabilization, 4 assessed oxidized low density
lipoprotein/vascular oxidant stress, 3 assessed end-stage renal disease, 3 assessed
fibrinogen/viscosity, 2 assessed endothelial function, 2 assessed acute coronary syndrome,
2 assessed aortic stenosis progression, and 1 each assessed hypertension, osteoporosis, ischemic
burden, Alzheimer’s disease, multiple sclerosis, and stroke (outcomes often overlapped).
Conclusion: Given the excellent safety and tolerability of statins as a class, full exploration
of their pleiotropic effects has the potential to provide additional benefits to many patients.
Keywords: atherosclerosis, cholesterol, clinical trials, endothelium, lipoproteins, metabolism,
myocardial infarction, pharmacology, vasculature
Introduction
Most biologically active molecules have “multiple actions”, which are referred to as
pleiotropic effects. There has been a major shift of interest in recent years towards
the pleiotropic effects of statins (Davignon 2004a). Those identified in humans
encompass effects on specific biochemical/physiological pathways or have impacts
on specific disease entities. The former include the ability to correct endothelial
dysfunction (Egashira et al 1994; Anderson et al 1995; Eichstädt et al 1995; Marchesi
et al 2000) and antioxidant (Giroux et al 1993; Anderson et al 1996; Aviram, Hussein,
et al 1998; Aviram, Rosenblat, et al 1998), antiinflammatory (Albert et al 2001;
Jialal et al 2001; Ridker, Rifai, et al 1998), and plaque-stabilizing effects (Corti et al
2001, 2002; Crisby et al 2001). These effects may result from inhibition of isoprenoid
synthesis, as illustrated in Figure 1. Some, or a combination of these properties result
in beneficial modification of various clinical entities. Statins have the ability to improve
survival in heart transplant recipients (Kobashigawa et al 1995; Wenke et al 1997)
and decrease mortality in end-stage renal disease (Seliger et al 2002) and following
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percutaneous coronary interventions (Chan et al 2002,
2003). They may have a modest antihypertensive effect
(Abetel et al 1998; Borghi et al 2000), promote coronary
collateral circulation (Nishikawa et al 2002), improve
survival in heart failure (Horwich et al 2004), and may have
favorable effects on glucose metabolism and insulin
sensitivity (McFarlane et al 2002). These effects extend
beyond the cardiovascular realm to include clinical
conditions such as Alzheimer’s disease, dementia, multiple
sclerosis, and osteoporosis (see below). However, the clinical
relevance of many other pleiotropic effects is not clear. Some
fascinating emergent properties that were first shown in
experimental studies, such as the protective effect against
myocardial hypertrophy (Takemoto et al 2001), are now
being reported in humans (Lee et al 2002). Indeed, there is
growing evidence that statins are cardioprotective (for
review, see Davignon 2004).
The relative importance of each pleiotropic effect in
determining the clinical benefits of statin therapy remains
to be determined in clinical trials designed a priori to study
these properties. Such studies are particularly needed in view
of preliminary data suggesting that there may be serious
consequences of not initiating statin therapy in patients with
acute coronary syndromes (ACS) (Walter et al 2002).
Furthermore, observational studies suggesting that statin
administration may decrease the prevalence of Alzheimer’s
disease (Jick et al 2000; Wolozin et al 2000), the risk of
fracture (Meier et al 2000; Wang et al 2000), and delay the
onset of diabetes mellitus (Freeman et al 2001) have
important long-term clinical implications. This review
summarizes ongoing trials aimed at clarifying the role of
cardiovascular and noncardiovascular pleiotropic effects of
statins in humans (Table 1). Since pleiotropic effect is
defined here, as it should, as “multiple effects” of a drug,
there is no attempt in this review at dissociating effects
attributable to low-density lipoprotein cholesterol (LDL-C)
lowering from those that are not. In fact, this dissociation,
in most situations, is difficult to make for the simple reason
that inhibiting cholesterol synthesis at the level of
mevalonate formation will also inhibit the isoprene pathway,
which is responsible for small G-protein prenylation and
most of the pleiotropic effect of statins. In other words, it is
to be expected that in many instances inhibition of the two
effects should be correlated, although some, such as the
C-reactive protein (CRP) effect and the LDL-C reduction
are not and contribute independently to the risk of coronary
artery disease (CAD) (for reviews, see Liao 2002; Davignon
2004a).
Cardiovascular studies
Endothelial function
Impaired endothelial function has been associated with
increased risk of coronary events in patients with
atherosclerosis (Al Suwaidi et al 2000; Schächinger et al
2000; Heitzer et al 2001; Perticone et al 2001). Effects of
statins largely unrelated to cholesterol lowering have been
shown to improve endothelial function, increase myocardial
perfusion, and enhance the availability of nitric oxide
(Egashira et al 1994; Eichstädt et al 1995; Endres et al 1998;
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Figure 1 The mevalonate pathway. By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, statins interfere with the synthesis not only of
cholesterol but also of isoprenoid intermediates, such as geranylgeranyl pyrophosphate (PP), which contribute to oxidative stress and cellular proliferation and
migration. Inhibition of these isoprenoid intermediates may contribute to the pleiotropic effects of statin therapy. Abbreviations: FFP, farnesyl pyrophosphate;
GPP, geranylgeranyl pyrophosphate; IPP, isopentenyl pyrophosphate.Vascular Health and Risk Management 2005:1(1) 31
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Laufs et al 1998). In patients with hypercholesterolemia and
coronary heart disease, the endothelium-dependent
vasodilatory response may be improved by a statin and also
by an angiotensin-converting enzyme inhibitor; the
combination of these drugs is more effective than either
agent alone (Esper et al 2000).
BART
The Brachial Artery Vasoreactivity Trial (BART) is a
substudy of the Reversal of Atherosclerosis with Lipitor
(REVERSAL) trial. The BART substudy will evaluate the
comparative effects of the two statins on endothelial
function, assessed by high-frequency ultrasound
measurements of changes in arterial diameter, in a subset
of 200 patients.
MIRACL substudy
A substudy of the Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering (MIRACL) trial
(Schwartz et al 2001) will assess the effect of intensive
therapy with atorvastatin 80 mg/d on oxidized LDL and
endothelial function in ACS patients. Additional MIRACL
substudies will evaluate the effect of statin therapy on a
number of inflammatory and endothelial markers, including
serum amyloid A, interleukin-6, P selectin, E selectin,
soluble vascular cell adhesion molecule, CD 40, and
intercellular adhesion molecule-1. The first of these
substudies, which demonstrates that the decline in
inflammatory markers following an acute coronary
syndrome is potentiated by atorvastatin (34% in 16 weeks),
has been published (Kinlay et al 2003). More recently,
another substudy of MIRACL showed that this statin had
only a modest effect on the plasma levels of the
proinflammatory, prothrombotic cytokine soluble CD40
ligand (sCD40L), but it abrogated the increased risk of
recurrent cardiovascular events associated with high levels
of sCD40L (Kinlay et al 2004). Finally, results of the effect
of atorvastatin in MIRACL on oxidized LDL in ACS was
also published, showing that atorvastatin reduced the risk
associated with elevated proinflammatory oxidized
phospholipids (OxPL) on apolipoprotein B and promoted
their mobilization and clearance (Tsimikas et al 2004).
Table 1 Ongoing trials of the pleiotropic effects of statins
Triala Effect(s) under investigation Statin(s)
ADCLT Alzheimer’s disease Atorvastatin
ASTRONOMER Aortic stenosis progression Rosuvastatin, placebo
A-to-Z Inflammatory markers Simvastatin, short placebo arm
before low dose statin
AURORA Oxidized LDL, CRP Rosuvastatin
AVALON Arterial compliance Atorvastatin
BART Endothelial function Atorvastatin, pravastatin
BONES Bone mineral density Atorvastatin
CAP Inflammatory markers plus prothrombotic proapoptotic microparticles,  Atorvastatin
type III procollagen propeptide, F2α-isoprostane, interferon
gamma/interleukin-10 ratio
CORONA Congestive heart failure Rosuvastatin
GISSI HF Congestive heart failure Rosuvastatin
JUPITER High CRP levels Rosuvastatin
LEADe Alzheimer’s disease Atorvastatin
LUNAR Inflammatory and thrombotic markers Rosuvastatin
MIRACL Substudy Oxidized LDL, endothelial function, and inflammatory markers Atorvastatin
Simvastatin MS Study Multiple sclerosis Simvastatin
ORION Plaque stabilization and inflammatory markers Rosuvastatin
PROVE IT Role of inflammatory markers in ACS; fibrinogen Pravastatin, atorvastatin
PROXI Vascular oxidant stress; CRP, other inflammatory cytokines Pravastatin, atorvastatin
SAGE Plaque stabilization Atorvastatin, pravastatin
SEAS Aortic stenosis progression Simvastatin, ezetimibe
SHARP Chronic renal disease Ezetimibe + simvastatin
Ezetimibe + placebo
SPARCL Stroke Atorvastatin, placebo
STIM Inflammatory markers plus fibrinogen, oxidized LDL, platelet reactivity, viscosity Pravastatin, simvastatin
4D Diabetes on hemodialysis Atorvastatin, placebo
a See text for trial abbreviations. LDL, low-density lipoprotein; CRP, C-reactive protein; ACS, acute coronary syndromes.Vascular Health and Risk Management 2005:1(1) 32
Davignon and Leiter
Antiinflammatory effects, plaque
stabilization, antioxidant, and
anticoagulant activity
Inflammatory markers, particularly high-sensitivity
C-reactive protein (hsCRP), have received increasing
recognition as important risk markers for atherosclerosis
and coronary events (Ridker, Glynn, et al 1998; Ridker,
Rifai, et al 1998; Ridker et al 2000, 2002; Romano et al
2000; Blankenberg et al 2001). Indeed, hsCRP has been
shown to predict risk of a first myocardial infarction and
other cardiovascular events among apparently healthy
middle-aged men and women (Ridker, Buring, et al 1998;
Ridker, Glynn, et al 1998). Statins appear to have
antiinflammatory effects that decrease the risk of
cardiovascular events (Ridker, Rifai, et al 1998; Ridker et
al 1999; Jialal et al 2001; Van Wissen et al 2002). Initial
results from the Pravastatin Inflammation CRP Evaluation
(PRINCE) indicate that pravastatin treatment significantly
lowered median CRP levels by 14% (p < 0.001) (Albert et
al 2001). In the Diabetes Atorvastatin Lipid Intervention
(DALI) trial (Berkplanken et al 2001), atorvastatin 10 mg
and 80 mg significantly reduced CRP levels by 15%
(p = 0.012) and 47% (p < 0.001), respectively, in patients with
type 2 diabetes mellitus but without manifest cardiovascular
disease (Van de Ree et al 2003). In a prospective substudy
of the effects of statins on CRP in the Effects of Atorvastatin
vs Simvastatin on Atherosclerosis Progression (ASAP) trial,
greater reductions in hsCRP with atorvastatin (34%) vs
simvastatin (9%) (p < 0.02, between groups) after 2 years
were associated with significantly greater decreases in
carotid intima-media thickness, respectively –40.1% on
atorvastastin 80 mg/d and –19.7% on simvastatin 40 mg/d
(Van Wissen et al 2002). This is some of the first evidence
that the change in this inflammatory marker relates to a
change in atherosclerosis progression (r = 0.13, p = 0.03).
The Reversal of Atherosclerosis with Lipitor
(REVERSAL) trial has demonstrated the effects of
aggressive (atorvastatin 80 mg/d) vs moderate (pravastatin
40 mg/d) lipid-lowering therapy on coronary atherosclerosis
regression or progression using intravascular ultrasound
technology (Nissen 2000). Intensive therapy was associated
with no progression in atheroma volume whereas
progresssion persisted with moderate therapy (Nissen et al
2004). A multivariate analysis is being carried out to
determine if the difference between the two regimens can
be accounted for by the significant difference (p < 0.0001,
Wilcoxon signed rank test) in hsCRP reduction (and changes
in other inflammatory markers) between the pravastatin
(5.2%) and atorvastatin (34.6%) groups. Furthermore, it was
recently reported that the best clinical outcomes were
obtained among statin-treated patients who achieved both
an LDL cholesterol < 70 mg/dL as well as a CRP levels
< 2.0 mg/dL (Ridker et al 2004). There is recent evidence
that the effect of aspirin is additive to that of pravastatin on
cardiovascular risk in a meta-analysis of the CARE and the
LIPID trials, implying that different antiinflammatory
pathways may be involved (Hennekens et al 2004).
In addition to antiinflammatory effects, statins may
reduce the risk of coronary events by contributing to plaque
stabilization through effects on matrix metalloproteinases,
macrophages, T cells, and vascular remodeling (Paoletti et
al 1997; Bellosta et al 1998; Corti et al 2001; Crisby et al
2001). There is now evidence from carotid artery specimens
obtained from patients pretreated or not with pravastatin
(Crisby et al 2001), simvastatin (Cipollone et al 2003), or
any statin (Molloy et al 2004) that these agents inhibit
markers of plaque destabilization in human carotids. Statins
attenuate activation of fibrinogen, factor V, factor XIII, and
prothrombin (Undas et al 2001), in addition to inhibiting
platelet aggregation (Aviram, Hussein, et al 1998). Findings
from the Atorvastatin and Thrombogenicity of the Carotid
Atherosclerotic Plaque (ATROCAP) study (Cortellaro et al
2002) assessed the thrombogenicity of atherosclerotic
carotid plaques from specimen obtained from 59 patients
scheduled for two-step bilateral endarterectomy and
randomly assigned placebo or atorvastatin before surgery.
Atorvastatin treatment 20 mg/d for 133 ± 63 days resulted
in significant reduction of macrophage content, tissue factor
antigen, tissue factor pathway inhibitor antigens, and tissue
factor activity demonstrating the reduction of the
inflammatory and thrombogenic phenotype of carotid
plaques by statin treatment.
Oxidative processes may be involved in the development
of plaque instability. Indeed, oxidized LDL was associated
with markers of plaque instability (increased number of
macrophages) in human carotid endarterectomy specimens
(Nishi et al 2002). Similarly, the severity of ACS has been
shown to correlate with plasma oxidized LDL (Ehara et al
2001). Statins have well known antioxidant properties
(Anderson et al 1996; Aviram, Hussein, et al 1998; Aviram,
Rosenblat, et al 1998), which are being evaluated in ongoing
trials (for reviews, see Davignon et al 2004; Mason et al
2004). Only recently was evidence obtained in humans that
statins can lower markers of oxidation. Simvastatin, for
instance, lowers urinary 8-Iso-PGF2α in hypercholesterolemicVascular Health and Risk Management 2005:1(1) 33
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individuals, an effect that is not enhanced by vitamin E
supplementation (De Caterina et al 2002). They also reduce
plasma nitrotyrosine (Shishebor, Aviles, et al 2003),
chlorotyrosine, and dityrosine (Shishebor, Brennan, et al
2003), which are other oxidative risk markers of
atherosclerosis.
There are a number of ongoing clinical trials using
different statins, which will provide us important
information as to whether the antiinflammatory and other
effects discussed above will translate into cardiovascular
event reduction.
AURORA
A study to evaluate the Use of Rosuvastatin in subjects On
Regular hemodialysis: an Assessment of survival and
cardiovascular events (AURORA) is a prospective,
randomized, double-blind, placebo-controlled study
investigating whether statin therapy can reduce all-cause
mortality and incidence of major cardiovascular events in
patients with end-stage renal disease who are on chronic
hemodialysis, irrespective of their baseline lipid status.
AURORA will randomize approximately 2700 men and
women aged 50–80 years who have been undergoing
hemodialysis for ≥ 3 months to rosuvastatin 10 mg/d or
placebo. The primary end points are time from random-
ization to death from any cause and time to major
cardiovascular event (earliest occurrence of nonfatal stroke,
nonfatal myocardial infarction, or cardiovascular death). The
study will also evaluate the effects of rosuvastatin on
oxidized LDL and CRP at 3 and 12 months post-
randomization. Enrollment of patients from Europe, Canada,
and Australia began in January 2003; follow-up is expected
to continue for 4 years. The design was presented at the
World Congress of Nephrology in 2003 (Fellström et al
2003).
4D (Die Deutsche Diabetes Dialyse Studie)
The 4D study is looking at the effects of atorvastatin 20 mg
daily vs placebo in 1200 hyperlipidemic patients with
diabetes type 2 on hemodialysis treatment for no more than
two years with a follow up of at least 2.5 years. The objective
is to improve cardiovascular mortality and nonfatal
myocardial infarction (MI) (Wanner et al 1999). The results
are expected in 2004.
SHARP
In addition, the SHARP (Study of Heart and Renal
Protection) trial (Baigent and Landry 2003), comparing
simvastatin 20 mg plus ezetimibe 10 mg daily with simvastatin
20 mg plus placebo, is currently enrolling 9000 patients with
chronic kidney disease (serum creatinine ≥ 130 µmol/L in
women and ≥ 150 µmol/L in men) or receiving dialysis. The
primary end point is time to a first major vascular event
(defined as nonfatal MI or cardiac death, nonfatal or fatal
stroke, or revascularization), with the secondary end points
including progression of end stage renal disease in the
nondialysis patients. This study will answer the question as
to whether additional LDL-C lowering through a non-statin
mediated mechanism will result in additional clinical benefit
with results expected in 2009.
A-to-Z trial
The A (for Aggrastat)-to-Z (for Zocor) Trial is a two-phase,
multicenter, randomized, controlled, double-blind trial
designed to investigate the clinical efficacy and tolerability
of early treatment with simvastatin 40 mg/d for 30 days
followed by simvastatin 80 mg/d thereafter in tirofiban-
treated ACS patients randomized to receive enoxaparin or
unfractionated heparin in conjunction with aspirin (Blazing
et al 2001). A substudy of this trial evaluates plasma samples
taken at 4 and 8 months to determine whether early
aggressive statin therapy reduces the levels of inflammatory
markers and if such reductions are associated with decreased
cardiovascular event rates. The Z phase of the A-to-Z trial,
comparing 40–80 mg/d simvastatin with placebo (4 months)
followed by 20 mg/d of simvastatin over two years on
cardiovascular event rates in ACS patients, was published
recently (De Lemos et al 2004). It failed to achieve the
prespecified end point, seemingly because of fewer events
than anticipated from power calculation. Several cases of
myopathy and rhabdomyolysis were reported at the high
doses. CRP levels were measured. A comparison made in
an editorial by Nissen (2004) between A-to-Z, MIRACL,
and PROVE-IT indicated that another contributing factor
might have been the relatively weak effect of simvastatin,
as compared with atorvastatin, on CRP reduction, reflecting
weaker antiinflammatory properties.
CAP
The Comparative Atorvastatin Pleiotropic effects (CAP) trial
is a double-blind, randomized, multicenter (France and
Canada) trial comparing atorvastatin 10 and 80 mg/d over a
26-week period in 300 subjects with coronary athero-
sclerosis, LDL cholesterol levels of ≤ 150 mg/dL
(≤ 3.87 mmol/L), and plasma hsCRP levels of ≥ 1.5 mg/L
but < 15 mg/L. The relative efficacy of these two doses willVascular Health and Risk Management 2005:1(1) 34
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be compared for a number of known as well as putative
pleiotropic effects, including plasma hsCRP, interleukin-6,
interleukin-18, soluble intercellular adhesion molecule-1,
soluble vascular cell adhesion molecule-1, soluble
E-selectin, prothrombotic proapoptotic microparticles, type
III procollagen propeptide, F2α-isoprostane, and interferon
gamma/interleukin-10 ratio, a measure of circulating
lymphocyte activation.
JUPITER
Primary prevention of cardiovascular events with
rosuvastatin 20 mg/d is being assessed in 15 000 patients
with low levels of LDL cholesterol (< 130 mg/dL), but
elevated levels of CRP (> 2.0 mg/L) in a long-term,
randomized, double-blind, placebo-controlled trial entitled:
The Justification for the Use of statins in Primary prevention:
an Intervention Trial Evaluating Rosuvastatin (JUPITER;
see Ridker and JUPITER Study Group 2003).
LUNAR
The LUNAR (Limiting UNdertreatment of lipids in ACS
with Rosuvastatin) study (Schuster and Fox 2004) is
comparing the effects over 12 weeks of rosuvastatin 20 or
40 mg daily with atorvastatin 80 mg daily on lipoprotein
fractions and CRP in 1836 subjects with a baseline
LDL > 70 mg/dL. A substudy will compare the effects of
these statins on additional inflammatory and thrombotic
markers.
ORION
The effect of moderate vs aggressive lipid lowering with
rosuvastatin on carotid atheroma volume will be assessed
by magnetic resonance imaging in the Outcome of
Rosuvastatin treatment on carotid artery atheroma: a
magnetic resonance Imaging Observation (ORION), a
prospective, randomized, double-blind, parallel-group trial.
Approximately 42 men and women aged ≥ 18 years, with
LDL-C levels between 100 and 250 mg/dL (2.6 and
6.5 mmol/L) and moderate asymptomatic carotid artery
stenosis, will be randomized to receive rosuvastatin 5 mg
(n = 21) or 80 mg (n = 21) once daily for 2 years. The primary
end point is change in carotid atheroma volume. Secondary
end points include changes in lesion composition as
determined by magnetic resonance imaging, carotid intima-
media thickness by ultrasound, and concentrations
of inflammatory markers and atherogenic lipoproteins
and apolipoproteins.
PROVE IT
The Pravastatin or Atorvastatin Evaluation and Infection
Therapy (PROVE IT) trial (Cannon et al 2002) compared
pravastatin 40 with atorvastatin 80 mg/d for secondary
prevention in ACS patients with total cholesterol levels
≤ 240 mg/dL (6.2 mmol/L). Four thousand one hundred and
sixty two patients were randomized, and the results showed
a greater protection of the more intensive therapy on deaths
or major cardiovascular events. A 16% reduction in the
hazard ratio for the primary end point favored more
aggressive LDL-C lowering with atorvastatin over moderate
LDL-C lowering with pravastatin (p = 0.005). This
supplemental benefit emerged after only 30 days. Substudies
of PROVE IT will examine the role of inflammatory markers
in precipitating events in ACS patients and the effect of
pravastatin treatment on these markers and on fibrinogen
levels.
PROXI
The primary objective of the PRavastatin and atorvastatin
effects on OXidative stress and Inflammation (PROXI) trial
is to compare the effects of pravastatin 40 mg and
atorvastatin 10 and 80 mg with placebo on vascular oxidant
stress and inflammatory cytokines, including CRP. Urinary
isoprostane F2α-VI will be measured at baseline and at
4 months. Patients aged 18–80 years with no history of
cardiovascular disease and an LDL-C level between
130 mg/dlL (3.36 mmol/L) and 220 mg/dL (5.68 mmol/L)
will be enrolled; the enrollment goal is 30 patients per
treatment arm. Additional analysis will determine if the
effects observed with pravastatin are independent of changes
in LDL-C.
STIM
The Statin Therapy & Immunological Mediators (STIM)
trial has 4 treatment arms with 18 patients each: pravastatin
40 mg, simvastatin 20 and 80 mg, and placebo. This trial
will evaluate the effect of statin therapy on fibrinogen,
platelet reactivity, and plasma viscosity as well as on
oxidized LDL. In addition, STIM will evaluate inflammatory
cytokines, including CRP, interleukins, monocyte
chemoattractant protein-1, tumor necrosis factor-α, and the
tumor necrosis factor-α receptor.
Hypertension
Recent findings (Abetel et al 1998; Borghi et al 2000)
suggest that statins may have antihypertensive effects thatVascular Health and Risk Management 2005:1(1) 35
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are independent of lipid lowering. The cholesterol-lowering
arm of the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT) (Sever et al 2003) was designed to test the
hypothesis that combination therapy with a statin (ator-
vastatin 10 mg) and antihypertensive agents (amlodipine ±
perindopril or atenolol ± bendroflumethiazide) provides an
incremental benefit to antihypertensive therapy plus placebo
in further decreasing the risk of cardiovascular events. The
cholesterol-lowering arm was terminated after a median
follow-up of 3.3 years because of the significant benefit
observed with atorvastatin in reducing the risk of nonfatal
MI and fatal coronary heart disease (36%, p = 0.0005) (Sever
et al 2003). Possible synergistic effects between statins and
antihypertensive agents on blood pressure will be assessed
when the blood pressure-lowering arm of the trial concludes.
AVALON
AVALON is a randomized, placebo-controlled trial with
3 treatment phases – double-blind, single-blind, and open-
label – and an enrollment goal of 1000 hyperlipidemic and
hypertensive patients. The objectives are to determine
whether combination therapy with atorvastatin and
amlodipine is superior to monotherapy with either drug in
decreasing the calculated risk of cardiovascular disease, and
to assess the effect of dual therapy on arterial compliance.
Data are expected in 2004.
Stroke
Evidence suggests that statins may act through a nonlipid-
lowering mechanism to reduce the risk of a cerebrovascular
accident (Bucher et al 1998; Collins et al 2002). In the recent
Heart Protection Study, patients both with and without a
prior history of stroke (n = 20 536) who were treated with
simvastatin 40 mg/d for 5 years experienced 25% fewer
strokes vs placebo (p < 0.0001); the reduction was primarily
due to a 30% decrease in risk of ischemic stroke (Collins et
al 2002). Recent results from the Prospective Study of
Pravastatin in the Elderly at Risk (PROSPER) trial
(Shepherd et al 2002), however, showed no significant effect
of pravastatin treatment on stroke prevention in elderly
patients, although there was a trend toward reduction in the
incidence of transient ischemic attacks (hazard ratio 0.75,
p = 0.051).
SPARCL
The Stroke Prevention by Aggressive Reduction of
Cholesterol Levels (SPARCL) trial evaluates the benefits
of atorvastatin 80 mg in reducing overall stroke in patients
free of coronary heart disease but who have experienced a
prior minor stroke or transient ischemic attack (Amarenco
et al 2003). This prospective, double-blind, randomized,
placebo-controlled trial will enroll approximately 4200
patients with LDL-C levels between 100 and 190 mg/dL
(2.59 and 4.91 mmol/L). Carotid endarterectomy specimens
will be studied in a subset of patients to examine the effect
of therapy on plaque composition. Follow-up will be
completed when 540 strokes have been recorded
(approximately 5 years). Study results are expected in 2005.
Aortic stenosis
Hyperlipidemia is associated with aortic stenosis (Rossebo
and Pedersen 2004). There is also evidence that statin
therapy may be associated with a reduced risk for
progression of aortic stenosis (AS) (Novaro et al 2001;
Bellamy et al 2002; Baghdasarian et al 2004). This has been
tentatively ascribed to the antiinflammatory properties of
statins (Pate et al 2003). This is currently being assessed in
two double-blind, randomized controlled studies.
In the ASTRONOMER (Aortic STenosis pROgressioN:
Observation Measuring Effect of Rosuvastatin) study,
442 Canadian patients with mild to moderate aortic stenosis
are being randomly allocated to 40 mg of rosuvastatin daily
vs placebo and followed for a minimum of 3 years. Primary
outcomes include increase in AV gradient and decrease in
AV area with secondary outcomes including cardiac death
and AV replacement. Expected completion is in 2008.
In contrast, the SEAS (Simvastatin and Ezetimibe in
Aortic Stenosis) study, (Rossebo and Pedersen 2004) is an
event driven 4-year study in which treatment with the
combination of simvastatin 40 mg plus ezetimibe 10 mg
daily is being compared with placebo in 1870 subjects with
moderate, asymptomatic, aortic stenosis. The primary end
point is a composite of major cardiovascular events including
cardiovascular death, aortic valve replacement surgery, and
congestive heart failure as a result of progression of AS,
nonfatal MI, coronary artery bypass grafting, percutaneous
coronary intervention, hospitalized unstable angina, and
nonhemorrhagic stroke. Expected completion is 2008.
Heart failure
CORONA (COntrolled ROsuvastatin multiNAtional trial
in heart failure) is comparing the effects of adding
rosuvastatin 10 mg or placebo to standard therapy on
cardiovascular outcomes in about 4950 elderly patients withVascular Health and Risk Management 2005:1(1) 36
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chronic symptomatic systolic heart failure. It is speculated
that the effects of statins on neoangiogenesis and
inhibition of proinflammatory cytokines, in addition to the
known beneficial effects on plaque stabilization and
endothelial function, may result in clinical benefit (Schuster
and Fox 2004).
In addition, the GISSI-HF (Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarcto myocardio Heart Failure)
is investigating the effects of rosuvastatin 10 mg or n-3 PUFA
(fish oil) on cardiovascular events in 7000 patients with
symptomatic heart failure of any etiology already receiving
standard treatment (Baldesseroni et al 2003).
Noncardiovascular studies
Dementia
Statin treatment has been reported to reduce the risk of
dementia (Jick et al 2000; Wolozin et al 2000), possibly by
causing a reduction in amyloid-β peptides in the
cerebrospinal fluid and brain (Wolozin et al 2000;
Fassbender et al 2001), and by promoting the activity of the
neuroprotective alpha-secretase ADAM 10 (A Disintegrin
And Metalloprotease) (Kojro et al 2001). Recent results from
PROSPER, however, showed no significant effects of
pravastatin therapy on slowing cognitive decline (Shepherd
et al 2002). Cognitive function was assessed by a telephone
questionnaire in the Heart Protection Study, but no effect of
simvastatin was observed (Collins et al 2002).
ADCLT
Recently, the results of the Alzheimer’s Disease (AD)
Cholesterol-Lowering Treatment (ADCLT) trial (Sparks et
al 2003) involving 63 patients with AD randomized to 80 mg
atorvastatin or placebo (1:1) daily for 12 months were
presented at the 8th International Montreal/Springfield
Symposium on Advances in Alzheimer’s Disease Therapy
2004. Although the study was relatively small (46 subjects
completed the trial), the atorvastatin therapy was associated
with a significant delay in cognitive deterioration assessed
by the Alzheimer’s Disease Assessment Scale-Cognition
(ADAS-cog) scores. These promising results certainly
support the importance of more definitive studies to be
carried out in this area.
CLASP
The randomized, double-blind, placebo-controlled, parallel-
group Cholesterol Lowering Agent to Slow Progression
(CLASP) of Alzheimer’s disease study will assess the
efficacy and safety of simvastatin in Alzheimer’s disease,
as measured by the ADAS-Cog and the Alzheimer’s Disease
Cooperative Study-Clinical Global Impression of Change
(ADCS-CGIC) scale. A total of 400 men and women aged
≥ 50 years with mild-to-moderate Alzheimer’s disease will
be randomized to 20 mg/d simvastatin or placebo for
6 weeks, followed by 40 mg/d simvastatin or placebo for
the rest of the 18-month study period. Mental status,
functional ability, behavioral disturbances, quality of life,
and economic indicators will also be evaluated. Study
completion is expected in 2005.
LEADe
The Lipitor’s Effect in Alzheimer’s Dementia (LEADe) trial
is an 80-week, randomized, multicenter, parallel-group,
double-blind study of the efficacy and safety of atorvastatin
plus an acetylcholinesterase inhibitor (donepezil) for the
treatment of mild-to-moderate Alzheimer’s disease. The trial
will enrol approximately 600 men and women at 60 sites
worldwide. Subjects will be randomized to 18 months of
treatment with either atorvastatin 80 mg plus donepezil
10 mg or to matching placebo plus donepezil 10 mg. The
primary objective of the study is to demonstrate the
superiority of the effects of combined treatment with
atorvastatin plus an acetylcholinesterase inhibitor compared
with acetylcholinesterase inhibitor alone on cognition, as
assessed by the ADAS-Cog, and on global functioning, as
assessed by the ADCS-CGIC scale. Study completion is
expected in 2006.
Multiple sclerosis
Cerebrosterol (24S-hydroxycholesterol) is increased in the
plasma of subjects with multiple sclerosis (Leoni et al 2002).
Simvastatin 80 mg/d was recently found to decrease plasma
levels of this sterol in hypercholesterolemic subjects
(Locatelli et al 2002). Atorvastatin was shown to prevent or
reverse chronic relapsing paralysis in an animal model of
autoimmune encephalomyelitis mimicking multiple
sclerosis (Youssef et al 2002), and lovastatin had a similar
effect in rats (Stanislaus et al 2002), effects that were
attributed to the immunomodulatory properties of statins
and to their induction of a bias toward Th2 cell
antiinflammatory cytokine production (Stanislaus et al 2002;
Youssef et al 2002) These findings prompted the undertaking
of an exploratory clinical trial.
SIMVASTATIN in multiple sclerosis
This open-label, single-arm study will assess the safety and
efficacy of 6 months of simvastatin 80 mg/d inVascular Health and Risk Management 2005:1(1) 37
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approximately 45 relapsing-remitting multiple sclerosis
patients aged 18–55 years. Treatment will be assessed by
magnetic resonance imaging. Eligible patients will have at
least one gadolinium-enhanced lesion after a 3-month
pretreatment period. Primary outcome is the difference
between the mean number of gadolinium-enhanced lesions
from the 3 monthly pretreatment cranial scans and the 3
scans performed at months 4, 5, and 6 of treatment.
Secondary outcomes include safety, volumes of gadolinium
lesions and number of new gadolinium lesions, the change
from baseline in neurologic assessments, and cytokine
activity. Preliminary analysis of pre- and post-treatment
magnetic resonance imaging data showed a decrease in mean
number of gadolinium lesions (–44%, p < 0.0001) and in
mean volume of gadolinium lesions (41%, p = 0.0018)
(Vollmer et al 2004). The positive results of this exploratory
trial warrant further investigation in a larger cohort of
patients.
Osteoporosis
Statin therapy may protect against bone fractures and
promote increased bone mineral density (Mundy et al 1999;
Chung et al 2000; Edwards et al 2000; Meier et al 2000;
Wang et al 2000; Pasco et al 2002). Two large case-control
studies (Meier et al 2000; Wang et al 2000) demonstrated
that use of statins is significantly associated with a decreased
risk of fracture. Other reports, however, did not confirm
these results (Wada et al 2000; Reid et al 2001). The first
prospective randomized study comparing the effect of
simvastatin (40 mg/d) to that of a lipid-lowering diet on bone
mineral density (BMD) has been published recently
(Lupattelli et al 2004). It showed a time-dependent increase
in BMD in postmenopausal women in femoral bone and
spine over two months, whereas there was a slight decrease
on the diet.
BONES
The benefit of atorvastatin 10–80 mg/d on BMD in
postmenopausal women at risk for osteoporosis will be
evaluated in BONES (not an acronym), a placebo-controlled,
randomized, dose-ranging trial. This 12-month trial will
enroll approximately 575 postmenopausal women 40–75
years of age with LDL-C levels between 130 mg/dL and
190 mg/dL (3.36 and 4.91 mmol/L). The primary end point
will be the change from baseline to week 52 in bone mineral
density. Changes in biochemical markers of bone
metabolism will also be assessed at 6 and 12 months. The
expected study completion date is 2005.
Rheumatoid arthritis and related
diseases
Although there are no trials aimed at studying the pleiotropic
effects of statins in this disease, recent small successful trials
have indirectly tested the immunomodulatory and anti-
inflammatory effects of statins in rheumatoid arthritis and
related diseases. Atorvastatin (McCarey et al 2004) and
simvastatin (Abud-Mendoza et al 2003) reduced clinical
manifestations and CRP levels in rheumatoid arthritis. The
latter report included cases of systemic lupus erythematosus
who responded well to therapy. A patient with a refractory
case of systemic juvenile idiopathic arthritis (Still’s disease),
who was prednisone-dependent, disabled, with a protracted
course, entered into remission with normalization of CRP,
loss of prednisone dependency, and loss of confinement to
a wheelchair with atorvastatin treatment (Ten Cate et al
2004). No doubt these conditions will be studied further
and future studies might include a panel of markers of
immunity and inflammation.
Conclusion
Available evidence indicates that many of the pleiotropic
effects of statins have application to a wide variety of clinical
conditions. Promising findings from preliminary
investigations have led to initiation of many ongoing clinical
trials to evaluate the potential role of statins in a number of
cardiovascular and noncardiovascular conditions. Results
from the ongoing clinical trials reviewed in this article are
anticipated over the next several years, and should help
clinicians and their patients make fully informed treatment
decisions.
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